Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report)’s share price hit a new 52-week high during trading on Monday . The company traded as high as $8.45 and last traded at $8.45, with a volume of 645 shares traded. The stock had previously closed at $8.38.
Analyst Upgrades and Downgrades
AMRX has been the topic of a number of analyst reports. Truist Financial lifted their price target on Amneal Pharmaceuticals from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Barclays lifted their price target on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. Finally, The Goldman Sachs Group lifted their price target on Amneal Pharmaceuticals from $6.25 to $8.00 and gave the stock a “buy” rating in a research note on Monday, May 6th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Amneal Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $9.00.
Check Out Our Latest Stock Analysis on AMRX
Amneal Pharmaceuticals Price Performance
Hedge Funds Weigh In On Amneal Pharmaceuticals
Several hedge funds have recently made changes to their positions in AMRX. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Amneal Pharmaceuticals during the fourth quarter valued at approximately $187,000. New York State Common Retirement Fund boosted its position in shares of Amneal Pharmaceuticals by 149.1% during the fourth quarter. New York State Common Retirement Fund now owns 122,003 shares of the company’s stock valued at $741,000 after purchasing an additional 73,020 shares in the last quarter. Truist Financial Corp bought a new stake in shares of Amneal Pharmaceuticals during the fourth quarter valued at approximately $395,000. Swiss National Bank bought a new stake in shares of Amneal Pharmaceuticals during the fourth quarter valued at approximately $1,291,000. Finally, TCG Advisory Services LLC bought a new stake in shares of Amneal Pharmaceuticals during the fourth quarter valued at approximately $91,000. 31.82% of the stock is owned by hedge funds and other institutional investors.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
Recommended Stories
- Five stocks we like better than Amneal Pharmaceuticals
- 3 Warren Buffett Stocks to Buy Now
- Eli Lilly’s Path to the Next Trillion Market Capitalization
- The How And Why of Investing in Oil Stocks
- Mobileye Global: CEO Makes $10 Million Bet on Future Strength
- How to Choose Top Rated Stocks
- 3 Stocks Increasing Dividend Payouts Ahead of Interest Rate Cuts
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.